Following recent breakthroughs, led by Allogene Therapeutics and Sana Biotechnology, it’s evident that 2025 is going to be a year marked by allogeneic innovation and clinical success.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
